SDC1 and plasma cell myeloma: As previously mentioned, SDC1 overexpression correlates with a malignant phenotype and, in addition, it is also implicated in resistance to cytotoxic or targeted therapeutics in breast cancer and multiple myeloma [157,184,185,186,187,188].